Celltrion Acquires Eli Lilly’s New Jersey Manufacturing Site for $330 Million
South Korea's Celltrion has signed a deal to acquire Eli Lilly's biopharmaceutical manufacturing facility in Branchburg, New Jersey for approximately $330 million12356.
The deal is aimed at mitigating potential US pharmaceutical tariffs and establishing a stable, local supply chain for Celltrion’s biopharmaceuticals in the US market126.
The facility covers about 391,000 square feet on 37 acres and will operate as a current good manufacturing practice (cGMP) production site, allowing Celltrion to begin operations immediately and bypass years of construction12.
Celltrion intends to invest a total of $1 billion in the site over time, which includes operations, facility expansion, and future growth1.
A contract manufacturing agreement was included:
50% of the plant’s capacity will continue to produce Eli Lilly products, with the other 50% allocated for Celltrion’s own products16.
All existing local staff will be retained, and Celltrion will establish a full local supply chain from production to sales in the US2.
Celltrion’s stock rose sharply following the announcement, closing up nearly 9%2.
This move supports Celltrion’s 'Made in USA' strategy in response to anticipated tariffs on imported pharmaceuticals that could be as high as 200%6.
Production of Celltrion products at the facility is expected to start by 2027, pending regulatory approval6.
Sources:
1. https://www.pharmaceuticalcommerce.com/view/celltrion-acquires-eli-lilly-production-plant
2. https://www.ajupress.com/view/20250923143121425
3. https://www.kedglobal.com/mergers-acquisitions/newsView/ked202509230006